샘플 요청 목록

 카트 문의
시장보고서
상품코드
1792746

인공관절 감염 치료 시장

Prosthetic Joint infection Treatment
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 576 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

인공관절 감염 치료 세계 시장은 2030년까지 1억 3,310만 달러에 달할 전망

2024년에 1억 720만 달러로 추정되는 인공관절 감염 치료 세계 시장은 분석 기간인 2024-2030년에 CAGR 3.7%로 성장하여 2030년에는 1억 3,310만 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 아미노글리코사이드는 CAGR 2.5%를 기록하며 분석 기간 종료시에는 2,920만 달러에 달할 것으로 예상됩니다. 당펩타이드 분야의 성장률은 분석 기간 동안 CAGR 4.5%로 추정됩니다.

미국 시장은 2,920만 달러로 추정되는 한편 중국은 CAGR 6.6%로 성장할 것으로 예측되는

미국의 인공관절 감염 치료 시장은 2024년에는 2,920만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 분석 기간 2024년부터 2030년까지 CAGR 6.6%로 성장하여 2030년에는 예측 시장 규모 2,640만 달러에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 1.6%와 2.8%로 예측됩니다. 유럽에서는 독일이 CAGR 2.1%로 성장할 것으로 예측됩니다.

세계의 인공관절 감염 치료 시장 - 주요 동향과 촉진요인 정리

인공관절 감염이 전문적인 치료 경로를 필요로 하는 주요 정형외과적 합병증으로 부상하고 있는 이유는 무엇일까?

인공관절 감염(PJI)은 인공관절 치환술 후 합병증 중 가장 심각하고 비용이 많이 드는 합병증 중 하나입니다. 인구의 고령화와 생활습관으로 인한 관절의 퇴행으로 전 세계적으로 인공고관절 및 인공슬관절 전치환술 건수는 지속적으로 증가하고 있으며, 감염률은 낮지만 임상적으로나 경제적으로 큰 부담으로 작용하고 있습니다. PJI는 보통 임플란트 표면에 미생물이 정착하여 면역반응과 기존 항생제에 내성을 가진 바이오필름을 형성하기 때문에 발생합니다. 이러한 감염은 수술, 항균제 치료, 장기적인 재활치료 등 복잡하고 장기적인 치료 요법을 필요로 합니다.

조기 발병 PJI(수술 후 3개월 이내)는 황색포도상구균과 같은 병원성이 강한 세균이 관여하는 경우가 많으며, 후기 또는 만발성 감염은 코아그라제 음성 포도상구균 및 기타 저악성 병원균에 의해 유발되는 경우가 많습니다. 이러한 구분은 감염의 만성 정도와 환자의 건강 상태에 따라 임플란트 삽입을 동반한 탈구술(DAIR)에서 2단계 인공관절 재치환술까지 다양한 치료법 결정에 영향을 미칩니다. 전 세계적으로, 특히 아시아태평양과 유럽에서 수술 건수가 증가함에 따라, 표준화된 증거에 기반한 PJI 치료 프로토콜의 필요성이 점점 더 커지고 있습니다.

다양한 환자군의 PJI를 관리하기 위해 어떤 수술적 및 약물적 접근법이 활용되고 있는가?

PJI 치료의 기본은 외과적 개입과 표적 항균제 치료의 병용입니다. 수술 후 단기간에 진단되는 급성 감염의 경우, 임플란트가 안정화되고 병원체가 밝혀진 경우 DAIR을 고려합니다. 그러나 만성 감염이나 치료 저항성 감염의 경우, 발치 후 2단계 재치환술을 시행하고 그 사이에 항생제를 충전한 스페이서를 사용하는 것이 여전히 표준입니다. 특히 유럽에서는 이환율 감소와 의료비 절감을 이유로 일차적 재치환술이 일부 사례에서 보급되고 있습니다.

메티실린 내성 황색포도상구균(MRSA)과 생물막 형성균이 많기 때문에 항생제 관리의 중요성은 매우 중요합니다. 경험적 치료는 보통 반코마이신이나 뎁토마이신과 같은 광범위 약물로 시작하여 배양 감수성에 따라 점진적으로 감량합니다. 시멘트 스페이서, 비드 또는 코팅을 통한 국소 항생제 전달은 전신 독성을 최소화하면서 감염 부위의 약물 농도를 증가시킵니다. 수술적 재치환술의 적응증이 아닌 환자에게는 장기 경구용 억제 항생제를 사용하기도 합니다. 개별화된 치료 계획은 병원균의 종류, 생물막의 성숙도, 환자의 면역 상태, 합병증 부담에 따라 형성됩니다.

진단 도구, 감염 관리 정책 및 병원 인프라가 치료 성과에 어떤 영향을 미치는가?

PJI의 정확한 진단은 여전히 어렵고, 많은 경우 혈청 마커(CRP, ESR 등), 활액 분석, 영상 진단, 미생물 배양을 결합해야 합니다. 차세대 염기서열분석(NGS), 중합효소 연쇄 반응(PCR), 알파-디펜신 면역측정법 등 첨단 진단법은 특히 배양 음성 사례에서 병원체 검출을 향상시키고 있습니다. PET-CT, 표지백혈구 신티그래피 등의 영상 진단 기술은 잠복감염이나 인공관절의 느슨해짐을 발견하는 데 도움을 주고 있습니다. 그러나 저자원 환경에서는 이러한 도구가 아직 널리 보급되지 않았습니다.

감염 예방은 여전히 가장 효과적인 전략이며, 엄격한 수술실 프로토콜, 층류 기류 시스템, 비강내 황색포도상구균 집락 형성에 대한 수술 전 선별 검사는 현재 많은 시설에서 표준이 되고 있습니다. 일부 병원에서는 정형외과 전문의, 감염 전문의, 임상 미생물학자가 참여하는 다학제적 PJI 팀을 통합하여 적시에 진단과 연계된 치료를 보장하고 있습니다. 감염률 모니터링, 재치환술 결과 추적 및 모범 사례 개선에 있어 시설 등록 및 전국 인공관절 치환술 데이터베이스의 역할이 점점 더 중요해지고 있습니다.

세계 인공관절 감염 치료 시장의 성장을 촉진하는 요인은 무엇인가?

세계 인공관절 감염 치료 시장의 성장 원동력은 인공관절 치환술 건수 증가, 환자 수명 증가, 감염 감시 강화 등입니다. 전 세계적으로 골관절염과 류마티스 관절염의 부담이 증가함에 따라 인공관절 치환술 건수는 꾸준히 증가하고 있으며, PJI의 발생률도 함께 증가할 것으로 예상됩니다. 또한, 당뇨병, 비만, 면역억제 등의 합병증을 앓고 있는 노인은 감염 위험이 높기 때문에 더욱 강력한 치료 옵션이 필요합니다.

새로운 항생제 제제, 바이오필름을 표적으로 하는 약물, 박테리오파지 요법 등이 조사되고 있으며, 의약품의 기술 혁신도 한몫을 하고 있습니다. 은 코팅 임플란트, 요오드 함침 인공관절, 항균 하이드로겔 코팅 등 항균 특성을 가진 정형외과용 생체재료의 성장은 감염 예방에 유망합니다. 병원은 임상적으로나 재정적으로 복잡한 PJI를 관리하기 위해 전용 감염 관리실, 재수술실, 장기 치료 지원 등에 투자하고 있습니다.

이 시장의 주요 기업으로는 Zimmer Biomet, Stryker, DePuy Synthes(Johnson & Johnson), Heraeus Medical, Biocomposites 등이 있습니다. 이들 기업은 항생제 충전 시멘트, 재치환용 임플란트, 진단키트 제공을 강화하고 있습니다. 임상 가이드라인이 계속 발전하고 치료 결과에 대한 데이터가 축적됨에 따라 인공관절 감염 치료 시장은 다학제적, 환자별, 비용 효율적인 치료 모델로 이동하며 고도화 및 규모가 확대될 것으로 예상됩니다.

부문

약제(아미노글리코사이드계 약제, 글리코 펩타이드계 약제, 리파마이신계 약제, 린코사미드계 약제, 페니실린계 약제, 기타 약제), 감염증(수술 전 감염증, 수술 후 감염증), 투여 경로(경구 투여, 정맥내 투여), 병원체(황색포도구균, 응고효소 음성 포도상구균, 칸디다속, 장구균속, 기타 병원체), 유통 채널(병원 약국, 소매 약국, 드럭스토어 유통 채널, 온라인 유통 채널)

조사 대상 기업 사례

  • Aurobindo Pharma Ltd.
  • AstraZeneca PLC
  • Cipla Ltd.
  • Dr. Reddy's Laboratories
  • Eli Lilly and Company
  • GSK plc
  • Lupin Limited
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Smith & Nephew plc
  • Stryker Corporation
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • TenNor Therapeutics Ltd.
  • Zimmer Biomet
  • DePuy Synthes(J&J)
  • 3M Healthcare

AI 통합

Global Industry Analysts는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 일반적인 LLM 및 업계 고유의 SLM 쿼리를 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM 25.08.27

Global Prosthetic Joint infection Treatment Market to Reach US$133.1 Million by 2030

The global market for Prosthetic Joint infection Treatment estimated at US$107.2 Million in the year 2024, is expected to reach US$133.1 Million by 2030, growing at a CAGR of 3.7% over the analysis period 2024-2030. Aminoglycosides, one of the segments analyzed in the report, is expected to record a 2.5% CAGR and reach US$29.2 Million by the end of the analysis period. Growth in the Glycopeptides segment is estimated at 4.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$29.2 Million While China is Forecast to Grow at 6.6% CAGR

The Prosthetic Joint infection Treatment market in the U.S. is estimated at US$29.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$26.4 Million by the year 2030 trailing a CAGR of 6.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.6% and 2.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.1% CAGR.

Global Prosthetic Joint Infection Treatment Market - Key Trends & Drivers Summarized

Why Are Prosthetic Joint Infections Emerging as a Major Orthopedic Complication Requiring Specialized Treatment Pathways?

Prosthetic joint infections (PJIs) are among the most serious and costly complications following joint arthroplasty procedures. While the global volume of total hip and knee replacements continues to rise due to aging populations and lifestyle-related joint degeneration, infection rates-though low-pose a high clinical and economic burden. PJIs typically occur due to microbial colonization of the implant surface, forming biofilms that are resistant to immune response and conventional antibiotics. These infections necessitate complex, prolonged treatment regimens involving surgery, antimicrobial therapy, and long-term rehabilitation.

Early-onset PJIs (within three months post-surgery) often involve virulent organisms such as Staphylococcus aureus, while delayed or late infections are frequently caused by coagulase-negative staphylococci and other low-grade pathogens. These distinctions influence treatment decisions, which may range from debridement with implant retention (DAIR) to two-stage revision arthroplasty, depending on infection chronicity and patient health. As surgical volumes increase globally-particularly in Asia-Pacific and Europe-the need for standardized, evidence-based PJI treatment protocols is becoming increasingly urgent.

Which Surgical and Pharmaceutical Approaches Are Being Utilized to Manage PJIs Across Different Patient Profiles?

The cornerstone of PJI treatment is surgical intervention combined with targeted antimicrobial therapy. In acute infections diagnosed within a short post-operative window, DAIR is considered if the implant remains stable and the pathogen is known. However, in chronic or treatment-resistant infections, explantation followed by a two-stage revision remains the gold standard, with antibiotic-loaded spacers used during the interim. One-stage revisions are gaining ground in select cases, particularly in Europe, due to reduced morbidity and healthcare cost savings.

Antibiotic stewardship is crucial given the high prevalence of methicillin-resistant Staphylococcus aureus (MRSA) and biofilm-forming bacteria. Empirical therapy typically begins with broad-spectrum agents such as vancomycin or daptomycin, followed by de-escalation based on culture sensitivity. Local antibiotic delivery via cement spacers, beads, or coatings enhances drug concentration at the infection site while minimizing systemic toxicity. Long-term oral suppressive antibiotics may be used in patients who are not candidates for surgical revision. Personalized treatment plans are shaped by pathogen type, biofilm maturity, patient immune status, and comorbidity burden.

How Are Diagnostic Tools, Infection Control Policies, and Hospital Infrastructure Influencing Treatment Outcomes?

Accurate diagnosis of PJIs remains challenging, often requiring a combination of serum markers (e.g., CRP, ESR), synovial fluid analysis, imaging, and microbiological culture. Advanced diagnostic modalities such as next-generation sequencing (NGS), polymerase chain reaction (PCR), and alpha-defensin immunoassays are improving pathogen detection, especially in culture-negative cases. Imaging techniques such as PET-CT and labeled leukocyte scintigraphy are aiding in identifying occult infections and prosthesis loosening. However, these tools are not yet widely available in low-resource settings.

Infection prevention remains the most effective strategy, with strict operating room protocols, laminar airflow systems, and preoperative screening for nasal S. aureus colonization now standard in many centers. Some hospitals are integrating multidisciplinary PJI teams involving orthopedic surgeons, infectious disease specialists, and clinical microbiologists to ensure timely diagnosis and coordinated care. Institutional registries and national joint replacement databases are playing a growing role in monitoring infection rates, tracking revision outcomes, and refining best practices.

What Factors Are Driving the Growth of the Global Prosthetic Joint Infection Treatment Market?

The growth in the global prosthetic joint infection treatment market is driven by rising arthroplasty volumes, increasing patient life expectancy, and enhanced infection surveillance. As the global burden of osteoarthritis and rheumatoid arthritis grows, the number of total joint replacements is expected to rise steadily-leading to a parallel increase in PJI incidence. Additionally, older adults with comorbidities such as diabetes, obesity, and immunosuppression are at higher risk for infection, necessitating more robust treatment options.

Pharmaceutical innovation is also playing a role, with new antibiotic formulations, biofilm-targeting agents, and bacteriophage therapies under investigation. Growth in orthopedic biomaterials with antimicrobial properties-such as silver-coated implants, iodine-impregnated prosthetics, and antimicrobial hydrogel coatings-holds promise for infection prevention. Hospitals are investing in dedicated infection control units, revision surgery suites, and long-term care support to manage the clinical and financial complexities of PJIs.

Leading players in this market include Zimmer Biomet, Stryker, DePuy Synthes (Johnson & Johnson), Heraeus Medical, and Biocomposites. These companies are enhancing their offerings in antibiotic-loaded cement, revision implants, and diagnostic kits. As clinical guidelines continue to evolve and data on treatment outcomes accumulate, the prosthetic joint infection treatment market is expected to grow in both sophistication and scale-shifting toward multidisciplinary, patient-specific, and cost-efficient care models.

SCOPE OF STUDY:

The report analyzes the Prosthetic Joint infection Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug (Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin, Other Drugs); Infection (Pre-operative Infection, Post-operative Infection); Administration Route (Oral Administration, Intravenous Administration); Pathogen (Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species, Other Pathogens); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 39 Featured) -

  • Aurobindo Pharma Ltd.
  • AstraZeneca PLC
  • Cipla Ltd.
  • Dr. Reddy's Laboratories
  • Eli Lilly and Company
  • GSK plc
  • Lupin Limited
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Smith & Nephew plc
  • Stryker Corporation
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • TenNor Therapeutics Ltd.
  • Zimmer Biomet
  • DePuy?Synthes (J&J)
  • 3M Healthcare

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Prosthetic Joint infection Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Joint Replacement Surgeries Drive Focus on Prosthetic Infection Prevention and Treatment
    • Growth in Antimicrobial Resistance Throws the Spotlight on Novel Therapeutic Development
    • Expansion of One-Stage and Two-Stage Revision Procedures Strengthens Market for Surgical Intervention Products
    • Collaboration With Biopharma Companies Spurs Innovation in Local Antibiotic Delivery Systems
    • Increasing Adoption of Bone Cement Spacers Embedded With Antimicrobials Enhances Infection Management
    • Regulatory Scrutiny Around Implantable Drug Delivery Encourages Clinical Innovation
    • Development of Targeted Biofilm Disruption Technologies Accelerates R&D in Adjunct Therapies
    • Advances in Smart Implant Technologies Enable Early Detection of Infection Markers
    • Integration of Wearable and Implantable Sensors Supports Remote Monitoring Post-Surgery
    • Rise in Post-Surgical Complications in Aging Population Expands Addressable Market
    • Clinical Guidelines Emphasizing Individualized Protocols Drive Demand for Customizable Treatment Kits
    • Investment in Biodegradable and Resorbable Carriers Supports Sustained Drug Release
    • Expansion of Hospital-Acquired Infection Surveillance Programs Strengthens Infection Control Initiatives
    • Use of Rapid Diagnostic Technologies Enhances Early Identification and Targeted Treatment
    • Strategic Hospital Partnerships Support End-User Adoption of Advanced Infection Management Solutions
    • Development of Multi-Drug Local Delivery Implants Enhances Therapeutic Efficacy
    • Increased Awareness Among Orthopedic Surgeons Promotes Adoption of Dual-Action Antimicrobial Approaches
    • Growth in Demand for Non-Systemic Antibiotic Therapies Reduces Toxicity Risk
    • Emergence of Next-Gen Antibiotics Tailored to Implant Infections Supports Market Differentiation
    • Supply Chain Optimization for Infection-Specific Surgical Kits Enhances Hospital Procurement Practices
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Prosthetic Joint infection Treatment Market Analysis of Annual Sales in US$ for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Prosthetic Joint infection Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Prosthetic Joint infection Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Aminoglycosides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Aminoglycosides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Aminoglycosides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Glycopeptides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Glycopeptides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Glycopeptides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Rifamycin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Rifamycin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Rifamycin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Lincosamide by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Lincosamide by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Lincosamide by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Penicillin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Penicillin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Penicillin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Intravenous Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Intravenous Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Intravenous Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Oral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Staphylococcus Aureus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Staphylococcus Aureus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Staphylococcus Aureus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Coagulase-negative Staphylococcus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Coagulase-negative Staphylococcus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Coagulase-negative Staphylococcus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Candida Species by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Candida Species by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 37: World 16-Year Perspective for Candida Species by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Enterococcus Species by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Enterococcus Species by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 40: World 16-Year Perspective for Enterococcus Species by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Other Pathogens by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Other Pathogens by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 43: World 16-Year Perspective for Other Pathogens by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 46: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 47: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 48: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 49: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 50: World Recent Past, Current & Future Analysis for Drug Stores Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 51: World Historic Review for Drug Stores Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 52: World 16-Year Perspective for Drug Stores Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 53: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 54: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 55: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 56: World Recent Past, Current & Future Analysis for Pre-operative Infection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 57: World Historic Review for Pre-operative Infection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 58: World 16-Year Perspective for Pre-operative Infection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 59: World Recent Past, Current & Future Analysis for Post-operative Infection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 60: World Historic Review for Post-operative Infection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 61: World 16-Year Perspective for Post-operative Infection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Prosthetic Joint infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 62: USA Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 63: USA Historic Review for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 64: USA 16-Year Perspective for Prosthetic Joint infection Treatment by Drug - Percentage Breakdown of Value Sales for Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 65: USA Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 66: USA Historic Review for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 67: USA 16-Year Perspective for Prosthetic Joint infection Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 68: USA Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 69: USA Historic Review for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 70: USA 16-Year Perspective for Prosthetic Joint infection Treatment by Pathogen - Percentage Breakdown of Value Sales for Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens for the Years 2014, 2025 & 2030
    • TABLE 71: USA Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 72: USA Historic Review for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 73: USA 16-Year Perspective for Prosthetic Joint infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 74: USA Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 75: USA Historic Review for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 76: USA 16-Year Perspective for Prosthetic Joint infection Treatment by Infection - Percentage Breakdown of Value Sales for Pre-operative Infection and Post-operative Infection for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 77: Canada Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Canada Historic Review for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 79: Canada 16-Year Perspective for Prosthetic Joint infection Treatment by Drug - Percentage Breakdown of Value Sales for Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 80: Canada Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Canada Historic Review for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 82: Canada 16-Year Perspective for Prosthetic Joint infection Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 83: Canada Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Canada Historic Review for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 85: Canada 16-Year Perspective for Prosthetic Joint infection Treatment by Pathogen - Percentage Breakdown of Value Sales for Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens for the Years 2014, 2025 & 2030
    • TABLE 86: Canada Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Canada Historic Review for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 88: Canada 16-Year Perspective for Prosthetic Joint infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 89: Canada Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Canada Historic Review for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 91: Canada 16-Year Perspective for Prosthetic Joint infection Treatment by Infection - Percentage Breakdown of Value Sales for Pre-operative Infection and Post-operative Infection for the Years 2014, 2025 & 2030
  • JAPAN
    • Prosthetic Joint infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 92: Japan Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Japan Historic Review for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 94: Japan 16-Year Perspective for Prosthetic Joint infection Treatment by Drug - Percentage Breakdown of Value Sales for Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 95: Japan Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Japan Historic Review for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 97: Japan 16-Year Perspective for Prosthetic Joint infection Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 98: Japan Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Japan Historic Review for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 100: Japan 16-Year Perspective for Prosthetic Joint infection Treatment by Pathogen - Percentage Breakdown of Value Sales for Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens for the Years 2014, 2025 & 2030
    • TABLE 101: Japan Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Japan Historic Review for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 103: Japan 16-Year Perspective for Prosthetic Joint infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 104: Japan Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Japan Historic Review for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 106: Japan 16-Year Perspective for Prosthetic Joint infection Treatment by Infection - Percentage Breakdown of Value Sales for Pre-operative Infection and Post-operative Infection for the Years 2014, 2025 & 2030
  • CHINA
    • Prosthetic Joint infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 107: China Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 108: China Historic Review for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 109: China 16-Year Perspective for Prosthetic Joint infection Treatment by Drug - Percentage Breakdown of Value Sales for Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 110: China Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 111: China Historic Review for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 112: China 16-Year Perspective for Prosthetic Joint infection Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 113: China Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 114: China Historic Review for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 115: China 16-Year Perspective for Prosthetic Joint infection Treatment by Pathogen - Percentage Breakdown of Value Sales for Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens for the Years 2014, 2025 & 2030
    • TABLE 116: China Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 117: China Historic Review for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 118: China 16-Year Perspective for Prosthetic Joint infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 119: China Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 120: China Historic Review for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 121: China 16-Year Perspective for Prosthetic Joint infection Treatment by Infection - Percentage Breakdown of Value Sales for Pre-operative Infection and Post-operative Infection for the Years 2014, 2025 & 2030
  • EUROPE
    • Prosthetic Joint infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 122: Europe Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 123: Europe Historic Review for Prosthetic Joint infection Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 124: Europe 16-Year Perspective for Prosthetic Joint infection Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 125: Europe Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Europe Historic Review for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 127: Europe 16-Year Perspective for Prosthetic Joint infection Treatment by Drug - Percentage Breakdown of Value Sales for Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 128: Europe Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Europe Historic Review for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 130: Europe 16-Year Perspective for Prosthetic Joint infection Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 131: Europe Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Europe Historic Review for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 133: Europe 16-Year Perspective for Prosthetic Joint infection Treatment by Pathogen - Percentage Breakdown of Value Sales for Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens for the Years 2014, 2025 & 2030
    • TABLE 134: Europe Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Europe Historic Review for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 136: Europe 16-Year Perspective for Prosthetic Joint infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 137: Europe Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Europe Historic Review for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 139: Europe 16-Year Perspective for Prosthetic Joint infection Treatment by Infection - Percentage Breakdown of Value Sales for Pre-operative Infection and Post-operative Infection for the Years 2014, 2025 & 2030
  • FRANCE
    • Prosthetic Joint infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 140: France Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 141: France Historic Review for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 142: France 16-Year Perspective for Prosthetic Joint infection Treatment by Drug - Percentage Breakdown of Value Sales for Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 143: France Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 144: France Historic Review for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 145: France 16-Year Perspective for Prosthetic Joint infection Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 146: France Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 147: France Historic Review for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 148: France 16-Year Perspective for Prosthetic Joint infection Treatment by Pathogen - Percentage Breakdown of Value Sales for Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens for the Years 2014, 2025 & 2030
    • TABLE 149: France Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 150: France Historic Review for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 151: France 16-Year Perspective for Prosthetic Joint infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 152: France Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 153: France Historic Review for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 154: France 16-Year Perspective for Prosthetic Joint infection Treatment by Infection - Percentage Breakdown of Value Sales for Pre-operative Infection and Post-operative Infection for the Years 2014, 2025 & 2030
  • GERMANY
    • Prosthetic Joint infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 155: Germany Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Germany Historic Review for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 157: Germany 16-Year Perspective for Prosthetic Joint infection Treatment by Drug - Percentage Breakdown of Value Sales for Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 158: Germany Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Germany Historic Review for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 160: Germany 16-Year Perspective for Prosthetic Joint infection Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 161: Germany Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Germany Historic Review for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 163: Germany 16-Year Perspective for Prosthetic Joint infection Treatment by Pathogen - Percentage Breakdown of Value Sales for Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens for the Years 2014, 2025 & 2030
    • TABLE 164: Germany Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Germany Historic Review for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 166: Germany 16-Year Perspective for Prosthetic Joint infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 167: Germany Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Germany Historic Review for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 169: Germany 16-Year Perspective for Prosthetic Joint infection Treatment by Infection - Percentage Breakdown of Value Sales for Pre-operative Infection and Post-operative Infection for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 170: Italy Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Italy Historic Review for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 172: Italy 16-Year Perspective for Prosthetic Joint infection Treatment by Drug - Percentage Breakdown of Value Sales for Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 173: Italy Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Italy Historic Review for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 175: Italy 16-Year Perspective for Prosthetic Joint infection Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 176: Italy Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Italy Historic Review for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 178: Italy 16-Year Perspective for Prosthetic Joint infection Treatment by Pathogen - Percentage Breakdown of Value Sales for Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens for the Years 2014, 2025 & 2030
    • TABLE 179: Italy Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Italy Historic Review for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 181: Italy 16-Year Perspective for Prosthetic Joint infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 182: Italy Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Italy Historic Review for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 184: Italy 16-Year Perspective for Prosthetic Joint infection Treatment by Infection - Percentage Breakdown of Value Sales for Pre-operative Infection and Post-operative Infection for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Prosthetic Joint infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 185: UK Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 186: UK Historic Review for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 187: UK 16-Year Perspective for Prosthetic Joint infection Treatment by Drug - Percentage Breakdown of Value Sales for Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 188: UK Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UK Historic Review for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 190: UK 16-Year Perspective for Prosthetic Joint infection Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 191: UK Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UK Historic Review for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 193: UK 16-Year Perspective for Prosthetic Joint infection Treatment by Pathogen - Percentage Breakdown of Value Sales for Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens for the Years 2014, 2025 & 2030
    • TABLE 194: UK Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UK Historic Review for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 196: UK 16-Year Perspective for Prosthetic Joint infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 197: UK Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UK Historic Review for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 199: UK 16-Year Perspective for Prosthetic Joint infection Treatment by Infection - Percentage Breakdown of Value Sales for Pre-operative Infection and Post-operative Infection for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 200: Spain Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Spain Historic Review for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 202: Spain 16-Year Perspective for Prosthetic Joint infection Treatment by Drug - Percentage Breakdown of Value Sales for Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 203: Spain Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Spain Historic Review for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 205: Spain 16-Year Perspective for Prosthetic Joint infection Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 206: Spain Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Spain Historic Review for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 208: Spain 16-Year Perspective for Prosthetic Joint infection Treatment by Pathogen - Percentage Breakdown of Value Sales for Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens for the Years 2014, 2025 & 2030
    • TABLE 209: Spain Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Spain Historic Review for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 211: Spain 16-Year Perspective for Prosthetic Joint infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 212: Spain Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Spain Historic Review for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 214: Spain 16-Year Perspective for Prosthetic Joint infection Treatment by Infection - Percentage Breakdown of Value Sales for Pre-operative Infection and Post-operative Infection for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 215: Russia Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Russia Historic Review for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 217: Russia 16-Year Perspective for Prosthetic Joint infection Treatment by Drug - Percentage Breakdown of Value Sales for Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 218: Russia Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Russia Historic Review for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 220: Russia 16-Year Perspective for Prosthetic Joint infection Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 221: Russia Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Russia Historic Review for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 223: Russia 16-Year Perspective for Prosthetic Joint infection Treatment by Pathogen - Percentage Breakdown of Value Sales for Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens for the Years 2014, 2025 & 2030
    • TABLE 224: Russia Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Russia Historic Review for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 226: Russia 16-Year Perspective for Prosthetic Joint infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 227: Russia Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Russia Historic Review for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 229: Russia 16-Year Perspective for Prosthetic Joint infection Treatment by Infection - Percentage Breakdown of Value Sales for Pre-operative Infection and Post-operative Infection for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 230: Rest of Europe Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Europe Historic Review for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 232: Rest of Europe 16-Year Perspective for Prosthetic Joint infection Treatment by Drug - Percentage Breakdown of Value Sales for Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 233: Rest of Europe Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Europe Historic Review for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 235: Rest of Europe 16-Year Perspective for Prosthetic Joint infection Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 236: Rest of Europe Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Europe Historic Review for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 238: Rest of Europe 16-Year Perspective for Prosthetic Joint infection Treatment by Pathogen - Percentage Breakdown of Value Sales for Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens for the Years 2014, 2025 & 2030
    • TABLE 239: Rest of Europe Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Europe Historic Review for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 241: Rest of Europe 16-Year Perspective for Prosthetic Joint infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 242: Rest of Europe Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Europe Historic Review for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 244: Rest of Europe 16-Year Perspective for Prosthetic Joint infection Treatment by Infection - Percentage Breakdown of Value Sales for Pre-operative Infection and Post-operative Infection for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Prosthetic Joint infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 245: Asia-Pacific Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 246: Asia-Pacific Historic Review for Prosthetic Joint infection Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 247: Asia-Pacific 16-Year Perspective for Prosthetic Joint infection Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 248: Asia-Pacific Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Asia-Pacific Historic Review for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 250: Asia-Pacific 16-Year Perspective for Prosthetic Joint infection Treatment by Drug - Percentage Breakdown of Value Sales for Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 251: Asia-Pacific Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Asia-Pacific Historic Review for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 253: Asia-Pacific 16-Year Perspective for Prosthetic Joint infection Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 254: Asia-Pacific Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Asia-Pacific Historic Review for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 256: Asia-Pacific 16-Year Perspective for Prosthetic Joint infection Treatment by Pathogen - Percentage Breakdown of Value Sales for Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens for the Years 2014, 2025 & 2030
    • TABLE 257: Asia-Pacific Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Asia-Pacific Historic Review for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 259: Asia-Pacific 16-Year Perspective for Prosthetic Joint infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 260: Asia-Pacific Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Asia-Pacific Historic Review for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 262: Asia-Pacific 16-Year Perspective for Prosthetic Joint infection Treatment by Infection - Percentage Breakdown of Value Sales for Pre-operative Infection and Post-operative Infection for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Prosthetic Joint infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 263: Australia Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Australia Historic Review for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 265: Australia 16-Year Perspective for Prosthetic Joint infection Treatment by Drug - Percentage Breakdown of Value Sales for Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 266: Australia Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Australia Historic Review for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 268: Australia 16-Year Perspective for Prosthetic Joint infection Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 269: Australia Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Australia Historic Review for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 271: Australia 16-Year Perspective for Prosthetic Joint infection Treatment by Pathogen - Percentage Breakdown of Value Sales for Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens for the Years 2014, 2025 & 2030
    • TABLE 272: Australia Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Australia Historic Review for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 274: Australia 16-Year Perspective for Prosthetic Joint infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 275: Australia Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Australia Historic Review for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 277: Australia 16-Year Perspective for Prosthetic Joint infection Treatment by Infection - Percentage Breakdown of Value Sales for Pre-operative Infection and Post-operative Infection for the Years 2014, 2025 & 2030
  • INDIA
    • Prosthetic Joint infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 278: India Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 279: India Historic Review for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 280: India 16-Year Perspective for Prosthetic Joint infection Treatment by Drug - Percentage Breakdown of Value Sales for Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 281: India Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 282: India Historic Review for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 283: India 16-Year Perspective for Prosthetic Joint infection Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 284: India Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 285: India Historic Review for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 286: India 16-Year Perspective for Prosthetic Joint infection Treatment by Pathogen - Percentage Breakdown of Value Sales for Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens for the Years 2014, 2025 & 2030
    • TABLE 287: India Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 288: India Historic Review for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 289: India 16-Year Perspective for Prosthetic Joint infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 290: India Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 291: India Historic Review for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 292: India 16-Year Perspective for Prosthetic Joint infection Treatment by Infection - Percentage Breakdown of Value Sales for Pre-operative Infection and Post-operative Infection for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 293: South Korea Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 294: South Korea Historic Review for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 295: South Korea 16-Year Perspective for Prosthetic Joint infection Treatment by Drug - Percentage Breakdown of Value Sales for Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 296: South Korea Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 297: South Korea Historic Review for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 298: South Korea 16-Year Perspective for Prosthetic Joint infection Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 299: South Korea Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 300: South Korea Historic Review for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 301: South Korea 16-Year Perspective for Prosthetic Joint infection Treatment by Pathogen - Percentage Breakdown of Value Sales for Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens for the Years 2014, 2025 & 2030
    • TABLE 302: South Korea Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 303: South Korea Historic Review for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 304: South Korea 16-Year Perspective for Prosthetic Joint infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 305: South Korea Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 306: South Korea Historic Review for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 307: South Korea 16-Year Perspective for Prosthetic Joint infection Treatment by Infection - Percentage Breakdown of Value Sales for Pre-operative Infection and Post-operative Infection for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 308: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Rest of Asia-Pacific Historic Review for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 310: Rest of Asia-Pacific 16-Year Perspective for Prosthetic Joint infection Treatment by Drug - Percentage Breakdown of Value Sales for Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 311: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Rest of Asia-Pacific Historic Review for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 313: Rest of Asia-Pacific 16-Year Perspective for Prosthetic Joint infection Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 314: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Rest of Asia-Pacific Historic Review for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 316: Rest of Asia-Pacific 16-Year Perspective for Prosthetic Joint infection Treatment by Pathogen - Percentage Breakdown of Value Sales for Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens for the Years 2014, 2025 & 2030
    • TABLE 317: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Rest of Asia-Pacific Historic Review for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 319: Rest of Asia-Pacific 16-Year Perspective for Prosthetic Joint infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 320: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Rest of Asia-Pacific Historic Review for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 322: Rest of Asia-Pacific 16-Year Perspective for Prosthetic Joint infection Treatment by Infection - Percentage Breakdown of Value Sales for Pre-operative Infection and Post-operative Infection for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Prosthetic Joint infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 323: Latin America Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 324: Latin America Historic Review for Prosthetic Joint infection Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 325: Latin America 16-Year Perspective for Prosthetic Joint infection Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 326: Latin America Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Latin America Historic Review for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 328: Latin America 16-Year Perspective for Prosthetic Joint infection Treatment by Drug - Percentage Breakdown of Value Sales for Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 329: Latin America Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 330: Latin America Historic Review for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 331: Latin America 16-Year Perspective for Prosthetic Joint infection Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 332: Latin America Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 333: Latin America Historic Review for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 334: Latin America 16-Year Perspective for Prosthetic Joint infection Treatment by Pathogen - Percentage Breakdown of Value Sales for Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens for the Years 2014, 2025 & 2030
    • TABLE 335: Latin America Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 336: Latin America Historic Review for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 337: Latin America 16-Year Perspective for Prosthetic Joint infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 338: Latin America Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 339: Latin America Historic Review for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 340: Latin America 16-Year Perspective for Prosthetic Joint infection Treatment by Infection - Percentage Breakdown of Value Sales for Pre-operative Infection and Post-operative Infection for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 341: Argentina Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 342: Argentina Historic Review for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 343: Argentina 16-Year Perspective for Prosthetic Joint infection Treatment by Drug - Percentage Breakdown of Value Sales for Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 344: Argentina Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 345: Argentina Historic Review for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 346: Argentina 16-Year Perspective for Prosthetic Joint infection Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 347: Argentina Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 348: Argentina Historic Review for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 349: Argentina 16-Year Perspective for Prosthetic Joint infection Treatment by Pathogen - Percentage Breakdown of Value Sales for Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens for the Years 2014, 2025 & 2030
    • TABLE 350: Argentina Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 351: Argentina Historic Review for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 352: Argentina 16-Year Perspective for Prosthetic Joint infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 353: Argentina Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 354: Argentina Historic Review for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 355: Argentina 16-Year Perspective for Prosthetic Joint infection Treatment by Infection - Percentage Breakdown of Value Sales for Pre-operative Infection and Post-operative Infection for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 356: Brazil Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 357: Brazil Historic Review for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 358: Brazil 16-Year Perspective for Prosthetic Joint infection Treatment by Drug - Percentage Breakdown of Value Sales for Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 359: Brazil Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 360: Brazil Historic Review for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 361: Brazil 16-Year Perspective for Prosthetic Joint infection Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 362: Brazil Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 363: Brazil Historic Review for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 364: Brazil 16-Year Perspective for Prosthetic Joint infection Treatment by Pathogen - Percentage Breakdown of Value Sales for Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens for the Years 2014, 2025 & 2030
    • TABLE 365: Brazil Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 366: Brazil Historic Review for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 367: Brazil 16-Year Perspective for Prosthetic Joint infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 368: Brazil Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 369: Brazil Historic Review for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 370: Brazil 16-Year Perspective for Prosthetic Joint infection Treatment by Infection - Percentage Breakdown of Value Sales for Pre-operative Infection and Post-operative Infection for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 371: Mexico Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 372: Mexico Historic Review for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 373: Mexico 16-Year Perspective for Prosthetic Joint infection Treatment by Drug - Percentage Breakdown of Value Sales for Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 374: Mexico Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 375: Mexico Historic Review for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 376: Mexico 16-Year Perspective for Prosthetic Joint infection Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 377: Mexico Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 378: Mexico Historic Review for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 379: Mexico 16-Year Perspective for Prosthetic Joint infection Treatment by Pathogen - Percentage Breakdown of Value Sales for Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens for the Years 2014, 2025 & 2030
    • TABLE 380: Mexico Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 381: Mexico Historic Review for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 382: Mexico 16-Year Perspective for Prosthetic Joint infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 383: Mexico Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 384: Mexico Historic Review for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 385: Mexico 16-Year Perspective for Prosthetic Joint infection Treatment by Infection - Percentage Breakdown of Value Sales for Pre-operative Infection and Post-operative Infection for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 386: Rest of Latin America Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 387: Rest of Latin America Historic Review for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 388: Rest of Latin America 16-Year Perspective for Prosthetic Joint infection Treatment by Drug - Percentage Breakdown of Value Sales for Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 389: Rest of Latin America Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 390: Rest of Latin America Historic Review for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 391: Rest of Latin America 16-Year Perspective for Prosthetic Joint infection Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 392: Rest of Latin America Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 393: Rest of Latin America Historic Review for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 394: Rest of Latin America 16-Year Perspective for Prosthetic Joint infection Treatment by Pathogen - Percentage Breakdown of Value Sales for Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens for the Years 2014, 2025 & 2030
    • TABLE 395: Rest of Latin America Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 396: Rest of Latin America Historic Review for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 397: Rest of Latin America 16-Year Perspective for Prosthetic Joint infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 398: Rest of Latin America Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 399: Rest of Latin America Historic Review for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 400: Rest of Latin America 16-Year Perspective for Prosthetic Joint infection Treatment by Infection - Percentage Breakdown of Value Sales for Pre-operative Infection and Post-operative Infection for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Prosthetic Joint infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 401: Middle East Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 402: Middle East Historic Review for Prosthetic Joint infection Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 403: Middle East 16-Year Perspective for Prosthetic Joint infection Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 404: Middle East Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 405: Middle East Historic Review for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 406: Middle East 16-Year Perspective for Prosthetic Joint infection Treatment by Drug - Percentage Breakdown of Value Sales for Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 407: Middle East Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 408: Middle East Historic Review for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 409: Middle East 16-Year Perspective for Prosthetic Joint infection Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 410: Middle East Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 411: Middle East Historic Review for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 412: Middle East 16-Year Perspective for Prosthetic Joint infection Treatment by Pathogen - Percentage Breakdown of Value Sales for Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens for the Years 2014, 2025 & 2030
    • TABLE 413: Middle East Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 414: Middle East Historic Review for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 415: Middle East 16-Year Perspective for Prosthetic Joint infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 416: Middle East Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 417: Middle East Historic Review for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 418: Middle East 16-Year Perspective for Prosthetic Joint infection Treatment by Infection - Percentage Breakdown of Value Sales for Pre-operative Infection and Post-operative Infection for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 419: Iran Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 420: Iran Historic Review for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 421: Iran 16-Year Perspective for Prosthetic Joint infection Treatment by Drug - Percentage Breakdown of Value Sales for Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 422: Iran Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 423: Iran Historic Review for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 424: Iran 16-Year Perspective for Prosthetic Joint infection Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 425: Iran Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 426: Iran Historic Review for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 427: Iran 16-Year Perspective for Prosthetic Joint infection Treatment by Pathogen - Percentage Breakdown of Value Sales for Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens for the Years 2014, 2025 & 2030
    • TABLE 428: Iran Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 429: Iran Historic Review for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 430: Iran 16-Year Perspective for Prosthetic Joint infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 431: Iran Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 432: Iran Historic Review for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 433: Iran 16-Year Perspective for Prosthetic Joint infection Treatment by Infection - Percentage Breakdown of Value Sales for Pre-operative Infection and Post-operative Infection for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 434: Israel Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 435: Israel Historic Review for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 436: Israel 16-Year Perspective for Prosthetic Joint infection Treatment by Drug - Percentage Breakdown of Value Sales for Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 437: Israel Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 438: Israel Historic Review for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 439: Israel 16-Year Perspective for Prosthetic Joint infection Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 440: Israel Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 441: Israel Historic Review for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 442: Israel 16-Year Perspective for Prosthetic Joint infection Treatment by Pathogen - Percentage Breakdown of Value Sales for Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens for the Years 2014, 2025 & 2030
    • TABLE 443: Israel Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 444: Israel Historic Review for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 445: Israel 16-Year Perspective for Prosthetic Joint infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 446: Israel Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 447: Israel Historic Review for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 448: Israel 16-Year Perspective for Prosthetic Joint infection Treatment by Infection - Percentage Breakdown of Value Sales for Pre-operative Infection and Post-operative Infection for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 449: Saudi Arabia Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 450: Saudi Arabia Historic Review for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 451: Saudi Arabia 16-Year Perspective for Prosthetic Joint infection Treatment by Drug - Percentage Breakdown of Value Sales for Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 452: Saudi Arabia Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 453: Saudi Arabia Historic Review for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 454: Saudi Arabia 16-Year Perspective for Prosthetic Joint infection Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 455: Saudi Arabia Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 456: Saudi Arabia Historic Review for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 457: Saudi Arabia 16-Year Perspective for Prosthetic Joint infection Treatment by Pathogen - Percentage Breakdown of Value Sales for Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens for the Years 2014, 2025 & 2030
    • TABLE 458: Saudi Arabia Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 459: Saudi Arabia Historic Review for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 460: Saudi Arabia 16-Year Perspective for Prosthetic Joint infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 461: Saudi Arabia Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 462: Saudi Arabia Historic Review for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 463: Saudi Arabia 16-Year Perspective for Prosthetic Joint infection Treatment by Infection - Percentage Breakdown of Value Sales for Pre-operative Infection and Post-operative Infection for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 464: UAE Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 465: UAE Historic Review for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 466: UAE 16-Year Perspective for Prosthetic Joint infection Treatment by Drug - Percentage Breakdown of Value Sales for Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 467: UAE Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 468: UAE Historic Review for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 469: UAE 16-Year Perspective for Prosthetic Joint infection Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 470: UAE Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 471: UAE Historic Review for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 472: UAE 16-Year Perspective for Prosthetic Joint infection Treatment by Pathogen - Percentage Breakdown of Value Sales for Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens for the Years 2014, 2025 & 2030
    • TABLE 473: UAE Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 474: UAE Historic Review for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 475: UAE 16-Year Perspective for Prosthetic Joint infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 476: UAE Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 477: UAE Historic Review for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 478: UAE 16-Year Perspective for Prosthetic Joint infection Treatment by Infection - Percentage Breakdown of Value Sales for Pre-operative Infection and Post-operative Infection for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 479: Rest of Middle East Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 480: Rest of Middle East Historic Review for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 481: Rest of Middle East 16-Year Perspective for Prosthetic Joint infection Treatment by Drug - Percentage Breakdown of Value Sales for Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 482: Rest of Middle East Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 483: Rest of Middle East Historic Review for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 484: Rest of Middle East 16-Year Perspective for Prosthetic Joint infection Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 485: Rest of Middle East Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 486: Rest of Middle East Historic Review for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 487: Rest of Middle East 16-Year Perspective for Prosthetic Joint infection Treatment by Pathogen - Percentage Breakdown of Value Sales for Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens for the Years 2014, 2025 & 2030
    • TABLE 488: Rest of Middle East Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 489: Rest of Middle East Historic Review for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 490: Rest of Middle East 16-Year Perspective for Prosthetic Joint infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 491: Rest of Middle East Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 492: Rest of Middle East Historic Review for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 493: Rest of Middle East 16-Year Perspective for Prosthetic Joint infection Treatment by Infection - Percentage Breakdown of Value Sales for Pre-operative Infection and Post-operative Infection for the Years 2014, 2025 & 2030
  • AFRICA
    • Prosthetic Joint infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 494: Africa Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 495: Africa Historic Review for Prosthetic Joint infection Treatment by Drug - Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 496: Africa 16-Year Perspective for Prosthetic Joint infection Treatment by Drug - Percentage Breakdown of Value Sales for Aminoglycosides, Glycopeptides, Rifamycin, Lincosamide, Penicillin and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 497: Africa Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 498: Africa Historic Review for Prosthetic Joint infection Treatment by Administration Route - Intravenous Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 499: Africa 16-Year Perspective for Prosthetic Joint infection Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 500: Africa Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 501: Africa Historic Review for Prosthetic Joint infection Treatment by Pathogen - Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 502: Africa 16-Year Perspective for Prosthetic Joint infection Treatment by Pathogen - Percentage Breakdown of Value Sales for Staphylococcus Aureus, Coagulase-negative Staphylococcus, Candida Species, Enterococcus Species and Other Pathogens for the Years 2014, 2025 & 2030
    • TABLE 503: Africa Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 504: Africa Historic Review for Prosthetic Joint infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 505: Africa 16-Year Perspective for Prosthetic Joint infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 506: Africa Recent Past, Current & Future Analysis for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 507: Africa Historic Review for Prosthetic Joint infection Treatment by Infection - Pre-operative Infection and Post-operative Infection Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 508: Africa 16-Year Perspective for Prosthetic Joint infection Treatment by Infection - Percentage Breakdown of Value Sales for Pre-operative Infection and Post-operative Infection for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제